AbbVie’s state government affairs director told the committee that discounts are applied post‑fill without claim‑level verification and that 340B incentives may reduce uptake of lower‑cost biosimilars while increasing covered‑entity margins on commercial patients.

Federal and state officials and policy experts briefed the committee on how the 340B discount program works, HRSA's planned rebate-pilot (Jan 2027), and ongoing litigation that could shape program implementation.